Emerging new concepts of myocardial laser revascularization  by Beranek, Jiri T.
use. The analogy of a comparison between “unproven herbal
approach versus tested scientific study” must be considered.
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Emerging new concepts of myocardial laser revas-
cularization
To the Editor:
Zenati, Cohen, and Griffith1 express support for the devel-
opment of centers in which different revascularization proce-
dures would be performed in the same patient by teams com-
posed of interventional cardiologists and cardiovascular
surgeons. Will myocardial laser revascularization (MLR),
either percutaneous or surgical, find its place in such team-
work when its original idea of perfusion of the left ventricle
from its cavity is no longer valid?2
In the meantime, a new concept trying to explain why MLR
has been beneficial to some patients has emerged: angiogen-
esis as a nonspecific response of the myocardium to injury.
All the same, this concept is usually considered unfit to serve
as a vehicle for MLR because this procedure leads only rarely
to the improvement of objective parameters such as cardiac
perfusion and function, exercise capacity, and survival.2
Before MLR is abandoned, we must be sure that it (1) has
been used correctly and (2) was applied to suitable patients. I
am afraid this has not always been the case.
Angiogenesis fulfills its purpose only if a source of oxy-
genated blood is available. This condition provided, angio-
genesis diminishes ischemia solely if it leads to the develop-
ment of collateral vessels linking the ischemic with the
well-perfused myocardium.3 In agreement with these con-
cepts, cardiomyocyte death induced by MLR would lead to
inflammatory angiogenesis and wound healing reaction.
Newly formed capillaries would connect blood vessels of the
lased ischemic region with blood vessels of neighboring well-
perfused areas. The angiogenesis would not subside after the
healing of laser channels because friction between noncom-
pliant laser channel scars and the contractile surrounding
myocardium would induce continuous injury and inflamma-
tion.4 New capillaries would not regress because of a pressure
gradient between the well-perfused myocardium and the
ischemic region.3 The remodeling of capillary-sized collater-
als into arterioles and arteries would complete the revascular-
ization, that is, the collateralization of the ischemic region.
Contrary to the above hypotheses, MLR has been used
mostly in patients with diffuse multivessel end-stage coro-
nary artery disease with contraindications to percutaneous
transluminal coronary angioplasty and coronary artery
bypass grafting. It is obvious that angiogenesis is of no use if
the whole ventricle is ischemic. On the contrary, the use of
MLR in combination with coronary artery bypass grafting
and/or coronary angioplasty (as it would be practiced in inte-
grated revascularization centers) is an excellent idea. The
conventional techniques would provide the source of well-
oxygenated blood wherever possible, and MLR would facili-
tate the development of collateral vessels in the areas inac-
cessible for traditional revascularization. It is worthy of note
that Mirhoseini, Shelgikar, and Cayton,5 the inventors of
MLR, used this method in combination with coronary artery
bypass grafting when they started to apply it to patients. This
undoubtedly explains their success. Recently, Trehan and col-
leagues6 used MLR in combination with minimally invasive
coronary artery bypass grafting and claimed excellent results.
All this suggests that MLR, if used in conjunction with other
methods of revascularization, will find its place in the thera-
peutic armamentarium used against ischemic heart disease.
Jiri T. Beranek
4101 S Wappel Dr
Columbia, MO 65203
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Reply to the Editor:
We enjoyed reading Beranek’s comments and discussion of
myocardial laser revascularization (MLR). Our concept of
integrated coronary revascularization is in constant evolution,
as new techniques become available both to the cardiac sur-
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